Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Safety, Pharmacodynamics, and Pharmacokinetics Study of Intravenous Imprime PGG [PGG glucan] Injection in Healthy Adult Subjects

Trial Profile

Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Safety, Pharmacodynamics, and Pharmacokinetics Study of Intravenous Imprime PGG [PGG glucan] Injection in Healthy Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Feb 2016

At a glance

  • Drugs PGG-glucan (Primary)
  • Indications Chronic lymphocytic leukaemia; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Postoperative infections
  • Focus Adverse reactions
  • Most Recent Events

    • 25 Feb 2016 Results published in Investigational New Drugs: The Journal of New Anticancer Agents, as per Biothera media release.
    • 25 Feb 2016 Results published in Biothera media release.
    • 31 Oct 2008 Data will be presented at the International Society for Biological Therapy of Cancer on 01 November 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top